![Kevin Fitzgerald](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kevin Fitzgerald
Chief Tech/Sci/R&D Officer at
ALNYLAM PHARMACEUTICALS, INC.
Net worth: 5 M $ as of 31/08/2026
Profile
Currently, Kevin Fitzgerald occupies the position of Chief Scientific Officer & Senior Vice President at Alnylam Pharmaceuticals, Inc. He received an undergraduate degree from Cornell University and a doctorate from Princeton University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 05/03/2026 | 21,106 ( 0.02% ) | 5 M $ | 31/08/2026 | |
| 17/04/2026 | 17,578 ( 0.01% ) | 46 933 $ | 31/08/2026 |
Kevin Fitzgerald active positions
| Companies | Position | Start |
|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/09/2016 |
| OVID THERAPEUTICS INC. | Director/Board Member | 06/10/2021 |
Training of Kevin Fitzgerald
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
73
1st degree connections
4
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Ovid Therapeutics, Inc.
 Ovid Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Provides medicines to children and adults with neurological disorders | Health Technology |
Alnylam Pharmaceuticals, Inc.
 Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Princeton University
 Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
- Stock Market
- Insiders
- Kevin Fitzgerald
